Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells.

MLA

Amaro, Adriana, et al. “Guadecitabine Increases Response to Combined Anti-CTLA-4 and Anti-PD-1 Treatment in Mouse Melanoma in Vivo by Controlling T-Cells, Myeloid Derived Suppressor and NK Cells.” Journal of Experimental & Clinical Cancer Research (17569966), vol. 42, no. 1, Mar. 2023, pp. 1–24. EBSCOhost, https://doi.org/10.1186/s13046-023-02628-x.

APA

Amaro, A., Reggiani, F., Fenoglio, D., Gangemi, R., Tosi, A., Parodi, A., Banelli, B., Rigo, V., Mastracci, L., Grillo, F., Cereghetti, A., Tastanova, A., Ghosh, A., Sallustio, F., Emionite, L., Daga, A., Altosole, T., Filaci, G., Rosato, A., & Levesque, M. (2023). Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Journal of Experimental & Clinical Cancer Research (17569966), 42(1), 1–24. https://doi.org/10.1186/s13046-023-02628-x

Chicago

Amaro, Adriana, Francesco Reggiani, Daniela Fenoglio, Rosaria Gangemi, Anna Tosi, Alessia Parodi, Barbara Banelli, et al. 2023. “Guadecitabine Increases Response to Combined Anti-CTLA-4 and Anti-PD-1 Treatment in Mouse Melanoma in Vivo by Controlling T-Cells, Myeloid Derived Suppressor and NK Cells.” Journal of Experimental & Clinical Cancer Research (17569966) 42 (1): 1–24. doi:10.1186/s13046-023-02628-x.